Sandbox/v31
< Sandbox
Thymic Tumor, Resectable | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pathology Evaluation | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No Residual Tumor | Microscopic Residual Tumor | Macroscopic Residual Tumor | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Thymoma, no capsular invasion or thymic carcinoma, stage I | Thymoma or thymic carcinoma, capsular invasion present, stages II-IV | Thymoma | Thymic carcinoma | Thymoma | Thymic carcinoma | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Postoperative RT | Postoperative RT | Postoperative RT + Chemotherapy | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Surveillance for recurrence with CT every 6 month for 2 y, then annually every 5 y for thymic carcinoma and 10 y for thymoma | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Chemotherapy Regimens
| FIRST-LINE COMBINATION CHEMOTHERAPY REGIMENS | SECOND-LINE CHEMOTHERAPY | |
| CAP (preferred for thymoma) * Cisplatin 50 mg/m² IV day 1 * Doxorubicin 50 mg/m² IV day 1 * Cyclophosphamide 500 mg/m² IV day 1 Administered every 3 weeks |
PE * Cisplatin 60 mg/m² IV day 1 *Etoposide 120 mg/m²/d IV days 1 -3 Administered every 3 weeks |
Etoposide Ifosfamide Pemetrexed Octreotide (including LAR) + prednisone 5-FU and leucovirin Gemcitabine Paclitaxel |
| CAP with Prednisone * Cisplatin 30 mg/m² IV days 1-3 * Doxorubicin 20 mg/m²/d IV continuous infusion on days 1 to 3 * Cyclophosphamide 500 mg/m² IV on day 1 * Prednisone 100 mg/day on days 1-5 Administered every 3 weeks |
VIP * Etoposide 75 mg/m² on days 1-4 * Ifosfamide 1.2 g/m² on days 1-4 * Cisplatin 20 mg/m² on days 1-4 Administered every 3 weeks | |
| ADOC * Cisplatin 50 mg/m² IV day 1 * Doxorubicin 40 mg/m² IV day 1 * Vincristine 0.6 mg/m² IV day 3 * Cyclophosphamide 700 mg/m² IV day 4 Administered every 3 weeks |
Carboplatin/Paclitaxel (preferred for Thymic Carcinoma) * Carboplatin AUC 6 * Paclitaxel 225 mg/m² Administered every 3 weeks | |